Drugs / HLX15
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05679258 | Jan 2023 → Mar 2024 | plasma cell myeloma | Shanghai Henlius Biotech | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX15 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05679258 ↗ |
| Modality | Monoclonal antibody | “Recombinant anti-CD38 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.” NCT05679258 ↗ |
| Route | Intravenous | “A single dose (8 mg/kg) of HLX15 via intravenous infusion.” NCT05679258 ↗ |
| Target | CD38 | “Recombinant anti-CD38 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.” NCT05679258 ↗ |